Abatacept in B7-1–Positive Proteinuric Kidney Disease — NEJM

Abatacept in B7-1–Positive Proteinuric Kidney Disease — NEJM

A New Era of Podocyte-Targeted Therapy for Proteinuric Kidney Disease — NEJM

A New Era of Podocyte-Targeted Therapy for Proteinuric Kidney Disease — NEJM

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy — NEJM

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy — NEJM

APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease — NEJM

APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease — NEJM

New Therapies for Diabetic Kidney Disease — NEJM

New Therapies for Diabetic Kidney Disease — NEJM

The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade? — NEJM

The End of Dual Therapy with Renin–Angiotensin–Aldosterone System Blockade? — NEJM

Clinical prediction rule for RAS

http://www.ncbi.nlm.nih.gov/pubmed/9841602

http://www.ncbi.nlm.nih.gov/pubmed/16003186

http://www.ncbi.nlm.nih.gov/pubmed/15944997

Wonder if any of the attending uses this and what their experience is